Results 91 to 100 of about 8,252,790 (324)
No clear timeline for approval of cannabis-based painkiller in Ireland.
The Department of Health is still exploring how a cannabis-based painkiller could be legally prescribed for use in Ireland amid increasing approval for the drug’s availability in the EU.
core
Abstract: In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir ...
Lauren Hartsell, Crump +7 more
openaire +3 more sources
Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley +1 more source
New Serious Safety Warnings for Targeted Anticancer Agents After Their Initial FDA Approval
Background: New safety concerns about targeted anticancer agents (TAAs) often emerge in the first few years after their initial regulatory approval. Our aim was to determine whether new serious and potentially fatal adverse drug reactions (ADRs) continue
Dimitar Stefanovski +3 more
core +1 more source
The Drug Approval Process and the Information it Provides
By law, the commissioner of the Food and Drug Administration (FDA) is responsible for determining whether a new drug is safe and efficacious before it is approved for marketing in the U.S. and for monitoring its use after approval. This paper provides a
Hugh H. Tilson +4 more
core +1 more source
Landmark Alzheimer’s drug approval confounds research community
Asher Mullard
semanticscholar +1 more source
ClinicalTrials.gov and Drugs@FDA: A comparison of results reporting for new drug approval trials
Sponsors are required by federal law to submit summary results of applicable clinical trials (including those beyond phase 1 supporting U.S. Food and Drug Administration [FDA] new drug approvals) to ClinicalTrials.gov for public posting (1).
Lisa M. Schwartz +4 more
semanticscholar +1 more source
We present robust protocols for the preparation of supported lipid bilayers (SLBs) incorporating either Salmonella smooth LPS or outer membrane vesicles (OMVs). We use a combination of quartz crystal microbalance with dissipation (QCM‐D) and fluorescence microscopy to both characterize the SLBs of various compositions and to probe their interactions ...
Hudson P. Pace +6 more
wiley +1 more source
Investigating transcription factor dynamics in health and disease using FRAP
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj +3 more
wiley +1 more source
Drug Approval-Patent Linkage System in the US and Canada
- Drug approval-patent linkage is the practice of linking drug marketing approval to the patent status of the originator's product and not allowing the grant of marketing approval to any third party prior to the expiration of the patent term unless by ...
박실비아
core

